Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early, Risk Adapted CC-99282 + Rituximab Post CAR T-Cell Therapy for Non-Hodgkin's Lymphoma

NCT06209619 is registered in ClinicalTrials.gov with Nathan Denlinger as lead sponsor.

NCT NCT06209619
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06209619 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early, Risk Adapted CC-99282 + Rituximab Post CAR T-Cell Therapy for Non-Hodgkin's Lymphoma
Lead sponsor
Nathan Denlinger
Phase
Phase 1
Overall status
Recruiting
Start date
January 29, 2024
Completion date
December 31, 2026
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell non-hodgkin lymphoma-recurrent, b-cell non-hodgkin lymphoma-refractory, diffuse large b-cell lymphoma-recurrent, diffuse large b-cell lymphoma-refractory, follicular lymphoma-recurrent, follicular lymphoma-refractory, high grade b-cell lymphoma-recurrent, high grade b-cell lymphoma-refractory, primary mediastinal large b-cell lymphoma-recurrent, primary mediastinal large b-cell lymphoma-refractory, transformed indolent b-cell non-hodgkin lymphoma to diffuse large b-cell lymphoma-recurrent, transformed indolent b-cell non-hodgkin lymphoma to diffuse large b-cell lymphoma-refractory